Table 6 Univariate analysis of the association of treatment system -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours

Specialty responsible for starting treatment

pulmonary

185

18

1

34

1

52

1

internal medicine

33

9

3.50 (1.38-8.90)

0.009

5

1.02 (0.36-2.96)

0.96

14

0.43 (0.06-2.97)

0.39

general medicine

2

2

Inf³

1.00

0

1.05

1.00

2

0.23 (0.04-1.20)

0.08

other

11

3

4.43 (0.98-20.14)

0.05

3

2.35 (0.53-10.31)

0.26

6

0.61 (0.12-2.10)

0.37

Specialty responsible for ending treatment

pulmonary

161

8

1

34

1

42

1

internal medicine

29

7

6.13 (1.97-19.05)

0.002

5

1.03 (0.35-2.99)

0.96

12

2.00 (0.88-4.53)

0.10

general medicine

35

16

14.00 (5.21-37.65)

<0.001

2

0.41 (0.09-1.87)

0.25

18

3.00 (1.42-6.35)

0.004

other

6

1

3.72 (0.37-37.29)

0.26

1

0.41 (0.09-8.09)

0.91

2

1.42 (0.25-8.02)

0.69

Change of specialty responsible for treatment

no

174

16

1

32

1

48

1

yes

57

16

4.06 (1.83-9.02)

0.001

10

1.27 (0.56-2.86)

0.58

26

2.20 (1.19-4.09)

0.01

Number of cases per year for unit responsible for ending treatment

1 - 4

55

16

4.37 (1.86-10.28)

0.001

10

1.49 (0.63-3.50)

0.36

26

2.51 (1.30-4.84)

0.006

5 - 10

12

1

0.88 (0.10-7.56)

0.91

2

0.96 (0.19-4.76)

0.96

3

0.93 (0.24-3.64)

0.92

11 - 29

34

3

1.03 (0.27-3.96)

0.96

8

1.50 (0.59-3.80)

0.39

11

1.34 (0.59-3.03)

0.49

30 -

129

12

1

22

1

34

1

Treatment group

standard treatment A

132

18

1

17

1

35

1

standard treatment B

24

5

2.69 (0.82-8.82)

0.10

9

5.14 (1.82-14.49)

0.002

14

3.88 (1.58-9.53)

0.003

standard treatment C

17

1

0.40 (0.05-3.11)

0.37

2

0.82 (0.17-3.91)

0.80

3

0.59 (0.16-2.19)

0.43

standard treatment D

19

1

0.41 (0.05-3.37)

0.41

5

2.19 (0.69-6.95)

0.18

6

1.28 (0.45-3.62)

0.64

other combination

34

6

1.70 (0.60-4.84)

0.32

9

2.70 (1.05-6.96)

0.04

15

2.19 (1.00-4.77)

0.049

ineffective

5

1

1.35 (0.14-12.76)

0.80

0

0

1.00

1

0.69 (0.07-6.41)

0.74

Change in treatment group

no

159

22

1

22

1

44

1

yes

72

10

1.00 (0.43-2.34)

0.99

20

2.12 (1.05-4.27)

0.04

30

1.56 (0.87-2.80)

0.13

Pause of treatment

no

169

25

1

22

1

47

1

yes

62

7

0.98 (0.39-2.45)

0.96

20

3.17 (1.55-6.46)

0.002

27

2.00 (1.09-3.66)

0.02

Pause during intensive phase¹

no

183

25

1

24

1

49

1

yes

47

6

1.40 (0.52-3.78)

0.51

18

4.37 (2.05-9.29)

<0.001

24

2.88 (1.43-5.78)

0.003

Pause during intensive phase, due to side effect

no

191

26

1

27

1

53

1

yes

40

6

1.68 (0.61-4.60)

0.32

15

4.04 (1.82-8.92)

0.001

21

2.85 (1.48-5.51)

0.002

Pause during continuation phase

no

171

12

1

25

1

37

1

yes

34

2

1.12 (0.23-5.36)

0.89

12

3.22 (1.40-7.40)

0.006

14

2.53 (1.17-5.50)

0.02

NA (other + ineffective)

26

18

5

23

Total

231

32

42

74